All fields are required.

Close Appointment form

Pharma Sanofi scores FDA nod for $270K nanobody drug Cablivi, its first from the Ablynx deal

  • Home
  • Pharma Sanofi scores FDA nod for $270K nanobody drug Cablivi, its first from the Ablynx deal
Pharma Sanofi scores FDA nod for $270K nanobody drug Cablivi, its first from the Ablynx deal
Pharma Sanofi scores FDA nod for $270K nanobody drug Cablivi, its first from the Ablynx deal

No Comments

Sanofi scores FDA nod for $270K nanobody drug Cablivi, its first from the Ablynx deal

Sanofi scooped up nanobody biotech Ablynx last year in a $4.5 billion deal—and now, the buyout may be starting to pay off. Cablivi, an Ablynx nanobody for a rare blood-clotting disorder, has snagged its FDA green light.

Cablivi scored its FDA nod in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytopenic purpura, or aTTP. The drug will be available late in the first quarter and cost $270,000 before rebates and discounts to treat a typical episode of aTTP, Sanofi said.

Sanofi figures that Cablivi’s improvement in patient outcomes will be attractive to patients and payers, and it sees the drug as a building block in a new blood disorder franchise. Analysts have said it could hit $500 million in peak sales worldwide. In a clinical study, the drug combined with plasma exchange and immunosuppression significantly bested standard of care in reducing patients’ platelet count response time, aTTP-related death, aTTP recurrence or a major thromboembolic event during treatment, the drugmaker reported.

Source: Fierce Pharma

  • Share This

Related Posts

Submit a comment

Your email address will not be published. Required fields are marked *

Leave a Reply

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>